ORITAVANCIN DIPHOSPHATE vs OSIMERTINIB: Which Drug Is Safer?
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
ORITAVANCIN DIPHOSPHATE vs OSIMERTINIB: Safety Overview
| Metric | ORITAVANCIN DIPHOSPHATE | OSIMERTINIB |
|---|---|---|
| Total FAERS Reports | 276 | 27,750 |
| Deaths Reported | 4 | 12,456 |
| Death Rate | 1.4% | 44.9% |
| Hospitalizations | 27 | 5,277 |
| Average Patient Age | 58.5 yrs | 68.2 yrs |
| % Female Patients | 39.2% | 66.0% |
| FDA Approval Date | Aug 6, 2014 | Nov 13, 2015 |
| Manufacturer | Melinta Therapeutics, LLC | AstraZeneca Pharmaceuticals LP |
| Route | INTRAVENOUS | ORAL |
| Marketing Status | Prescription | Prescription |